Annexin Pharmaceuticals carries out a directed share issue of approximately SEK 7 million to begin development in the cancer field
PRESS RELEASE19 December 2022 The Board of Directors of Annexin Pharmaceuticals AB (publ) (”Annexin Pharmaceuticals” or the “Company”) has today, with the support of the authorization from the annual general meeting held on 24 May 2022, resolved on a directed share issue of 7,368,421 shares with a deviation from the shareholders’ preferential rights, whereby the Company receives approximately SEK 7 million before the costs for the issue, corresponding to a subscription price of SEK 0.95 per share (the “Directed Share Issue”). The Directed Share Issue, which is directed to the five